Validation and comparison of clinical prediction rules for invasive candidiasis in intensive care unit patients: A matched case-control study

Critical Care

Volumn 15, Issue 4, 2011, Pages

  Hermsen, Elizabeth D ^a,b,c   Zapapas, Michelle K ^a   Maiefski, Melissa ^a   Rupp, Mark E ^b   Freifeld, Alison G ^b   Kalil, Andre C ^b  

^a NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Candidiasis; Clinical prediction rules; Prophylaxis

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID;

ABDOMINAL SURGERY; ADULT; ARTICLE; CASE CONTROL STUDY; CENTRAL VENOUS CATHETER; CONTROLLED STUDY; DIABETES MELLITUS; DIALYSIS; FEMALE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE UNIT; INTERMETHOD COMPARISON; INVASIVE CANDIDIASIS; LENGTH OF STAY; MALE; MEDICAL RECORD REVIEW; MORTALITY; OSTROSKY-ZEICHNER CLINICAL PREDICTION RULE; PANCREATITIS; PAPHITOU CLINICAL PREDICTION RULE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RATING SCALE; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TOTAL PARENTERAL NUTRITION; UNITED STATES; VALIDATION STUDY; AGED; CROSS INFECTION; METHODOLOGY; MIDDLE AGED; RISK ASSESSMENT; STANDARD;

ADULT; AGED; AGED, 80 AND OVER; CANDIDIASIS, INVASIVE; CASE-CONTROL STUDIES; CROSS INFECTION; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; NEBRASKA; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 80051619560     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10366     Document Type: Article

References (25)

1. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996, 9:499-511. 172907, 8894349.
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309-317. 10.1086/421946, 15306996.
3. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, Rangel-Frausto MS, Rinaldi MG, Saiman L, Wiblin RT, Wenzel RP, . National Epidemiology of Mycoses Survey (NEMIS) Study Group Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001, 33:177-186. 10.1086/321811, 11418877, National Epidemiology of Mycoses Survey (NEMIS) Study Group.
4. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998, 27:781-788. 10.1086/514955, 9798034.
5. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006, 43:25-31. 10.1086/504810, 16758414.
6. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49:3640-3645. 10.1128/AAC.49.9.3640-3645.2005, 1195428, 16127033.
7. Nolla-Salas J, Sitges-Serra A, León-Gil C, Martínez-González J, León-Regidor MA, Ibáñez-Lucia P, Torres-Rodríguez JM. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 1997, 23:23-30. 10.1007/s001340050286, 9037636.
8. Cruciani M, de Lalla F, Mengoli C. Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med 2005, 31:1479-1487. 10.1007/s00134-005-2794-y, 16172847.
9. Eggimann P, Francioli P, Bille J, Schneider R, Wu MM, Chapuis G, Chiolero R, Pannatier A, Schilling J, Geroulanos S, Glauser MP, Calandra T. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999, 27:1066-1072. 10.1097/00003246-199906000-00019, 10397206.
10. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002, 28:1708-1717. 10.1007/s00134-002-1540-y, 12447512.
11. Pelz RK, Hendrix CW, Swoboda SM, Diener-West M, Merz WG, Hammond J, Lipsett PA. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001, 233:542-548. 10.1097/00000658-200104000-00010, 1421284, 11303137.
12. Savino JA, Agarwal N, Wry P, Policastro A, Cerabona T, Austria L. Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. J Trauma 1994, 36:20-26. 10.1097/00005373-199401000-00004, 8295245.
13. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 2006, 57:628-638. 10.1093/jac/dki491, 16459344.
14. Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med 2005, 33:1928-1936. 10.1097/01.CCM.0000178352.14703.49, 16148461.
15. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 2005, 43:235-243. 10.1080/13693780410001731619, 16010850.
16. Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, Kauffman CA, Kett D, Larsen RA, Morrison V, Nucci M, Pappas PG, Bradley ME, Major S, Zimmer L, Wallace D, Dismukes WE, Rex JH. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007, 26:271-276. 10.1007/s10096-007-0270-z, 17333081.
17. Ostrosky-Zeichner L, Pappas PG, Shoham S, Reboli A, Barron MA, Sims C, Wood C, Sobel JD. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses 2011, 54:46-51. 10.1111/j.1439-0507.2009.01756.x, 19627509.
18. Playford EG, Lipman J, Kabir M, McBryde ES, Nimmo GR, Lau A, Sorrell TC. Assessment of clinical risk predictive rules for invasive candidiasis in a prospective multicentre cohort of ICU patients. Intensive Care Med 2009, 35:2141-2145. 10.1007/s00134-009-1619-9, 19756510.
19. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE, . European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821. 10.1086/588660, 2671227, 18462102, European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.
20. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology 2008, Philadelphia Lippincott Williams & Wilkins, 3.
21. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994, 220:751-758. 10.1097/00000658-199412000-00008, 1234477, 7986142.
22. Schuster MG, Edwards JE, Sobel JD, Darouiche RO, Karchmer AW, Hadley S, Slotman G, Panzer H, Biswas P, Rex JH. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 2008, 149:83-90.
23. León C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, Garnacho-Montero J, León MA, . EPCAN Study Group A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006, 34:730-737. 10.1097/01.CCM.0000202208.37364.7D, 16505659, EPCAN Study Group.
24. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia: a matched case-control study. Arch Intern Med 1989, 149:2349-2353. 10.1001/archinte.149.10.2349, 2802900.
25. Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Hammond JM, Hendrix CW. The diagnostic value of fungal surveillance cultures in critically ill patients. Surg Infect (Larchmt) 2000, 1:273-281.